Europe North America Region rs Gene OR P OR 2p23.3 rs65477402:2785436GPN1 A G 0.98 0.84 7.36E-04 0.80 2p23.3 rs65477412:2785592GPN1 A G 0.98 0.84 6.46E-04 0.80 2p23.3 rs46660072:2785649GPN1 C T 0.98 0.84 6.46E-04 0.80 2p23.3 rs15284022:2785751GPN1 A G 0.98 0.84 6.48E-04 0.80 4q23 rs12299844:1002393ADH1B A G Geno 0.53 3.52E-06 0.76 5p15.33 rs421284 5:1325590CLPTM1L G A Geno 1.19 5.62E-04 1.25 5p15.33 rs452932 5:1330253CLPTM1L G A Geno 1.19 5.72E-04 1.24 5p15.33 rs24478535:1333077CLPTM1L G A 1.00 1.18 9.02E-04 1.24 5p15.33 rs20170845:1334508CLPTM1L I D Geno 1.19 5.52E-04 1.24 5p15.33 rs467095 5:1336221CLPTM1L G A Geno 1.19 5.12E-04 1.25 5p15.33 rs455433 5:1336243CLPTM1L G A Geno 1.19 7.61E-04 1.24 5p15.33 rs460073 5:1336459CLPTM1L G A Geno 1.19 5.90E-04 1.24 5p15.33 rs1121553 5:1337070CLPTM1L G A Geno 1.19 5.09E-04 1.25 5p15.33 rs459961 5:1337106CLPTM1L T A Geno 1.19 5.38E-04 1.24 5p15.33 rs31484 5:1337906CLPTM1L T A Geno 1.19 7.09E-04 1.25 5p15.33 rs31487 5:1341101 CLPTM1L C G 1.00 1.19 7.25E-04 1.24 5p15.33 rs10462705:1343794CLPTM1L T C 0.97 0.75 1.87E-04 0.74 5p15.33 rs31490 5:1344458CLPTM1L A G Geno 1.18 1.21E-03 1.24 9p21.3 rs37312399:2197421CDKN2A G A Geno 1.15 8.41E-03 1.21 9p21.3 rs10757269:2205990CDKN2B-AC T 1.00 0.84 1.51E-03 0.81 9p21.3 rs20951449:2206013CDKN2B-AG A 1.00 0.84 1.66E-03 0.81 9p21.3 rs81810479:2206446CDKN2B-AA G Geno 1.19 2.10E-03 1.25 9p21.3 rs14128329:2207754CDKN2B-AG A Geno 1.16 6.26E-03 1.26 9q34.12 rs928674 9:1339520LAMC3 G A 0.89 1.31 6.48E-04 1.36 9q34.12 rs19971789:1339538LAMC3 C A Geno 1.29 1.52E-03 1.35 9q34.12 rs73658919:1339539LAMC3 G A 0.94 1.28 2.20E-03 1.38 Supplementary Table 5 Oral cancer results (P < 5 x10¬8 )
Chr:posa
Effect
allele Otherallele Info(Rsq.)b
d Fixed-effects meta-analysis
a SNP position according to NCBI genome build 37 (Hg19)
bGeno=genotyped, SNP, INFO, Rsq is the average across imputation batches. c Frequency of the effect allele.
North America South America
P OR P OR P
1.03E-05 0.915 2.56E-01 0.50 0.54 0.83 4.33E-08 0.34 1.03E-05 0.916 2.64E-01 0.50 0.54 0.83 3.97E-08 0.34 1.05E-05 0.917 2.69E-01 0.50 0.54 0.83 4.16E-08 0.33 1.03E-05 0.918 2.71E-01 0.50 0.54 0.83 4.15E-08 0.33 5.43E-02 0.363 7.33E-06 0.03 0.06 0.57 1.09E-09 0.02 9.77E-06 1.107 1.79E-01 0.48 0.44 1.20 2.14E-08 0.40 1.72E-05 1.098 2.16E-01 0.48 0.44 1.19 4.31E-08 0.39 1.61E-05 1.11 1.69E-01 0.47 0.43 1.19 4.52E-08 0.45 1.64E-05 1.107 1.77E-01 0.48 0.44 1.20 2.91E-08 0.44 8.90E-06 1.108 1.78E-01 0.50 0.45 1.20 1.77E-08 0.40 1.71E-05 1.111 1.66E-01 0.48 0.44 1.20 3.77E-08 0.46 1.46E-05 1.106 1.84E-01 0.48 0.44 1.20 3.05E-08 0.43 9.01E-06 1.106 1.88E-01 0.50 0.46 1.20 1.9E-08 0.39 1.64E-05 1.102 2.00E-01 0.48 0.44 1.20 3.43E-08 0.41 9.48E-06 1.1 2.14E-01 0.50 0.46 1.20 3.12E-08 0.36 1.70E-05 1.115 1.50E-01 0.48 0.43 1.20 3.25E-08 0.49 7.04E-05 0.693 2.62E-03 0.12 0.15 0.74 5.54E-10 0.85 1.91E-05 1.133 1.02E-01 0.47 0.42 1.20 3.6E-08 0.57 3.43E-04 1.452 2.21E-05 0.36 0.31 1.21 1.22E-08 0.07 1.44E-04 0.732 1.37E-03 0.72 0.76 0.81 7.78E-09 0.49 1.37E-04 0.726 1.04E-03 0.72 0.76 0.81 6.93E-09 0.44 7.27E-05 1.389 7.01E-04 0.29 0.24 1.24 3.8E-09 0.37 3.19E-05 1.354 1.76E-03 0.29 0.25 1.23 1.34E-08 0.33 5.63E-05 1.274 5.07E-02 0.14 0.12 1.33 2.09E-08 0.88 7.63E-05 1.314 1.98E-02 0.13 0.10 1.32 2.62E-08 0.92 3.54E-05 1.294 4.02E-02 0.13 0.10 1.33 3.96E-08 0.77
Meta-analysisd
Frq.c
Cases Frq.
c
